U.S Food and Drug Administration (USFDA) has concluded a Bioresearch Monitoring (BIMO) inspection at Alkem Laboratories’ Bioequivalence Center located at Taloja, Maharashtra. The said inspection conducted from March 10, 2025 to March 13, 2025. At the end of the inspection, no Form 483 was issued.
Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.